hailshadow-istockphoto-com
Hailshadow / iStockphoto.com
14 June 2018Americas

PTAB rejects IPR challenges to Gilead patents

The Patent Trial and Appeal Board (PTAB) has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
20 June 2018   Humanitarian organisation Médecins Sans Frontières has challenged a patent owned by Gilead in China.
Americas
24 July 2018   The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.
Biotechnology
20 July 2020   Biotechnology company Qiagen has failed in its bid to stop diagnostics company HandyLab from retaining a patent for a diagnostic system, according to a decision issued by the US Patent Trial and Appeal Board on Tuesday, July 14.

More on this story

Asia
20 June 2018   Humanitarian organisation Médecins Sans Frontières has challenged a patent owned by Gilead in China.
Americas
24 July 2018   The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.
Biotechnology
20 July 2020   Biotechnology company Qiagen has failed in its bid to stop diagnostics company HandyLab from retaining a patent for a diagnostic system, according to a decision issued by the US Patent Trial and Appeal Board on Tuesday, July 14.

More on this story

Asia
20 June 2018   Humanitarian organisation Médecins Sans Frontières has challenged a patent owned by Gilead in China.
Americas
24 July 2018   The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.
Biotechnology
20 July 2020   Biotechnology company Qiagen has failed in its bid to stop diagnostics company HandyLab from retaining a patent for a diagnostic system, according to a decision issued by the US Patent Trial and Appeal Board on Tuesday, July 14.